- Home
- JWN vs DNLI Comparison
JWN vs DNLI Comparison
Compare JWN & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JWN
- DNLI
- Stock Information
- Founded
- JWN 1901
- DNLI 2013
- Country
- JWN United States
- DNLI United States
- Employees
- JWN N/A
- DNLI N/A
- Industry
- JWN Clothing/Shoe/Accessory Stores
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JWN Consumer Discretionary
- DNLI Health Care
- Exchange
- JWN Nasdaq
- DNLI Nasdaq
- Market Cap
- JWN 4.0B
- DNLI 3.3B
- IPO Year
- JWN N/A
- DNLI 2017
- Fundamental
- Price
- JWN $24.10
- DNLI $21.93
- Analyst Decision
- JWN Hold
- DNLI Strong Buy
- Analyst Count
- JWN 14
- DNLI 13
- Target Price
- JWN $21.85
- DNLI $38.91
- AVG Volume (30 Days)
- JWN 3.8M
- DNLI 1.1M
- Earning Date
- JWN 03-04-2025
- DNLI 02-25-2025
- Dividend Yield
- JWN 3.15%
- DNLI N/A
- EPS Growth
- JWN 110.55
- DNLI N/A
- EPS
- JWN 1.55
- DNLI N/A
- Revenue
- JWN $15,112,000,000.00
- DNLI N/A
- Revenue This Year
- JWN $2.42
- DNLI N/A
- Revenue Next Year
- JWN $1.81
- DNLI $651.24
- P/E Ratio
- JWN $15.50
- DNLI N/A
- Revenue Growth
- JWN 3.56
- DNLI 204.74
- 52 Week Low
- JWN $16.79
- DNLI $14.56
- 52 Week High
- JWN $24.99
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- JWN 55.35
- DNLI 51.28
- Support Level
- JWN $24.00
- DNLI $18.52
- Resistance Level
- JWN $24.20
- DNLI $22.37
- Average True Range (ATR)
- JWN 0.09
- DNLI 1.31
- MACD
- JWN -0.04
- DNLI 0.31
- Stochastic Oscillator
- JWN 37.04
- DNLI 88.57
About JWN Nordstrom Inc.
Nordstrom is a fashion retailer that operates about 93 department stores and 280 off-price Nordstrom Rack stores. The company also operates both full- and off-price e-commerce sites, two clearance stores, and six Local locations. Nordstrom's largest merchandise categories are women's apparel (27% of 2023 sales), shoes (26% of 2023 sales), men's apparel (15% of 2023 sales), and beauty (13% of 2023 sales). Nordstrom, which traces its history to a shoe store opened in Seattle in 1901, continues to be partially owned and managed by members of the eponymous family.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.